PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 346-354

  Zhang, Long ^a   Liu, Menghan ^a   Jamil, Serwanja ^a   Han, Ruizhi ^a   Xu, Guochao ^a   Ni, Ye ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

Arginine deiminase; Cancer; Mice model; PEGylation; Pharmacodynamic pharmacokinetic

Indexed keywords

ARGININE; ARGININE DEIMINASE; FLUOROURACIL; MACROGOL; N HYDROXYSUCCINIMIDE; PEGARGIMINASE; SUCCINIMIDE CARBONATE; SUCCINIMIDE CARBOXYMETHYLATE; SUCCINIMIDE DERIVATIVE; SUCCINIMIDE PROPIONATE; SUCCINIMIDYL SUCCINATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYDROLASE; MACROGOL DERIVATIVE;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG RETENTION; ENZYME ENGINEERING; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; LIVER CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PEGYLATION; PROTEIN DEPLETION; PROTEIN MODIFICATION; PSEUDOMONAS; PSEUDOMONAS PLECOGLOSSICIDA; TUMOR VOLUME; ANIMAL; CHEMISTRY; DISEASE MODEL; ENZYMOLOGY; GENETICS; LIVER NEOPLASMS, EXPERIMENTAL; PROTEIN ENGINEERING;

MUS; PSEUDOMONAS PLECOGLOSSICIDA;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HYDROLASES; LIVER NEOPLASMS, EXPERIMENTAL; MICE; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; PSEUDOMONAS;

EID: 84920584118     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.042     Document Type: Article

References (27)

1. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J. Clin. Oncol 2004, 22:1815-1822.
2. Ascierto P.A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J. Clin. Oncol 2005, 23:7660-7668.
3. Ni Y., Liu Y., Schwaneberg U., Zhu L., Li N., Li L., et al. Rapid evolution of arginine deiminase for improved anti-tumor activity. Appl. Microbiol. Biotechnol 2011, 90:193-201.
4. Ni Y., Schwaneberg U., Sun Z.H. Arginine deiminase, a potential anti-tumor drug. Cancer Lett 2008, 261:1-11.
5. Wang M., Basu A., Palm T., Hua J., Youngster S., Hwang L., et al. Engineering an arginine catabolizing bioconjugate: biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis. Bioconjug. Chem 2006, 17:1447-1459.
6. Graham M.L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev 2003, 55:1293-1302.
7. Gong H., Zölzer F., von Recklinghausen G., Rössler J., Breit S., Havers W., et al. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem. Biophys. Res. Commun 1999, 261:10-14.
8. Gong H., Zölzer F., von Recklinghausen G., Havers W., Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 2000, 14:826-829.
9. Glazer E.S., Piccirillo M., Albino V., Di Giacomo R., Palaia R., Mastro A.A., et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J. Clin. Oncol 2010, 28:2220-2226.
10. Liu Y.M., Sun Z.H., Ni Y., Zheng P., Liu Y.P., Meng F.J. Isolation and identification of an arginine deiminase producing strain Pseudomonas plecoglossicida CGMCC2039. World J. Microbiol. Biotechnol 2008, 24:2213-2219.
11. 20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002, 62:5443-5450.
12. Takaku H., Matsumoto M., Misawa S., Miyazaki K. Anti-tumor activity of arginine deiminase from Mycoplasma arginine and its growth-inhibitory mechanism. Jpn. J. Cancer Res 1995, 86:840-846.
13. Li L., Li Z., Wang C., Xu D., Mariano P.S., Guo H., et al. The electrostatic driving force for nucleophilic catalysis in L-arginine deiminase: a combined experimental and theoretical study. Biochemistry 2008, 47:4721-4732.
14. Smith D.W., Ganaway R.L., Fahrney D.E. Arginine deiminase from Mycoplasma arthritidis. Structure-activity relationships among substrates and competitive inhibitors. J. Biol. Chem 1978, 253:6016-6020.
15. Takaku H., Takase M., Abe S., Hayashi H., Miyazaki K. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer 1992, 51:244-249.
16. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug. Chem 2001, 12:195-202.
17. Veronese F.M., Mero A., Pasut G. Protein PEGylation, basic science and biological applications. PEGylated Protein Drugs: Basic Science and Clinical Applications 2009, p11-p31. Birkhäuser Verlag, Basel. F.M. Veronese (Ed.).
18. Reddy K.R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother 2000, 34:915-923.
19. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov 2003, 2:214-221.
20. Xu L., Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J. Pharm. Sci 2011, 100:38-52.
21. Fishburn C.S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci 2008, 97:4167-4183.
22. Holtsberg F.W., Ensor C.M., Steiner M.R., Bomalaski J.S., Clark M.A. Poly (ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J. Control. Release 2002, 80:259-271.
23. Takaku H., Misawa S., Hayashi H., Miyazaki K. Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini. Jpn. J. Cancer Res 1993, 84:1195-1200.
24. Shen L.J., Shen W.C. Drug evaluation: ADI-PEG-20 - a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr. Opin. Mol. Ther 2006, 8:240-248.
25. Sun Z.H., Zheng P., Ni Y., Liu Y., Liu Y.P. An arginine deiminase producing strain and its application. Chin. Pat 2007, No. ZL200710107822.X.
26. Zhu L., Verma R., Roccatano D., Ni Y., Sun Z.H., Schwaneberg U. A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions. Chembiochem 2010, 11:2294-2301.
27. Zhang Y., Huo M., Zhou J., Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed 2010, 99:306-314.